"Additionally, Dr Byon served as Senior Medical Director at Juno Therapeutics, where as the
Global Clinical Development Lead he was instrumental in the clinical development of
orvacabtagene autoleucel (orva-cel/JCARH125) for relapsed/refractory multiple
myeloma and other novel CAR T-cell targets"
Excellent appointment team management, and yes he has runs on the board!
Juno Therapeutics was taken over for $6B.
CLL/SLL: Efficacy of CD19-Directed CAR T-Cell Therapy in Relapsed or Refractory Disease
Study details in the Ascot Post on 29 August 2023, for article reported in The Lancet.
https://ascopost.com/news/august-2023/cllsll-efficacy-of-cd19-directed-car-t-cell-therapy-in-relapsed-or-refractory-disease/?utm_source=pushly
Regards.
Ann: Imugene Appoints Dr John Byon as SVP Clinical Development, page-10
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |